S&P 500
7,697.86
+31.26
+0.41%
Dow
53,335.84
+273.89
+0.52%
Nasdaq
26,406.91
+189.08
+0.72%
NYSE Composite
24,616.39
+120.84
+0.49%
Russell 2000
2,964.14
+10.98
+0.37%
VIX
15.07
-0.13
-0.86%
BYSI · BeyondSpring Inc. Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Beyondspring Inc (BYSI)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.63
+0.01
(+2.14%)
● Market open
DAY'S RANGE
$0.63
$0.63
$0.63
52-WEEK RANGE
$0.63
$0.57
$2.44
What's happening
- BYSI is up 2.14% today, trading at $0.63. — Live quote
- Volume today (100) is well below its 3-month average of 479,790. (Finnhub fundamentals)
- Reports earnings on 2026-09-04, 1 day away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2024-06-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BYSI
-63.03%
vs S&P 500
-74.74%
1-YEAR RETURN
BYSI
-67.07%
vs S&P 500
-86.05%
6-MONTH RETURN
BYSI
-53.65%
3-MONTH RETURN
BYSI
-65.37%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-04-26 (Q1 2026)
$-0.05
Est. $—
2022-01-26 (Q4 2021)
$-0.24
Est. $-0.27
BEAT +10.9%
2021-10-26 (Q3 2021)
$-0.47
Est. $-0.38
MISS -22.9%
2021-07-26 (Q2 2021)
$-0.49
Est. $-0.33
MISS -47.4%
Valuation Measures & Ratios
Enterprise Value4$33.5M
Forward P/E50.31
PEG Ratio6—
Price / Sales (TTM1)27.79
Price / Book76.92
EV4 / Revenue24.80
EV4 / EBITDA—
Profit Margin-4750.48%
Operating Margin-4903.03%
Return on Equity (ROE8)-133.13%
Return on Assets (ROA9)-29.15%
Avg Volume (3M)479,790
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | — | $42.4M | — |
| P/E | — | — | — | -12.13 | — |
| Price/Book | — | — | — | -1.40 | — |
| ROE | — | — | — | 11.56% | — |
| ROA | — | — | — | -11.25% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,729,984
Change from Prior Settlement+21.62%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -4750.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -67.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BYSI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$1.7M | -$2.2M | -$1.8M | -$1.9M | -$2.6M | -$2.4M | -$2.6M | -$2.1M |
| Net income | -$849.0K | -$2.2M | -$1.5M | -$1.8M | $4.5M | -$2.1M | -$4.0M | -$3.2M |
| EPS (diluted) | — | — | — | $-0.10 | — | — | $-0.04 | — |
| EPS (basic) | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.11 | $-0.05 | $-0.10 | $-0.08 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $14.6M | $18.4M | $25.9M | $29.5M | $31.0M | $37.1M | $34.3M | $24.8M |
| Total liabilities | $50.6M | $48.8M | $49.9M | $49.3M | $48.6M | $49.8M | $48.6M | $48.3M |
| Stockholders' equity | -$35.6M | -$34.5M | -$32.2M | -$31.8M | -$30.2M | -$28.3M | -$32.9M | -$26.8M |
| Total current assets | $9.9M | $13.5M | $20.9M | $24.4M | $25.7M | $31.5M | $28.6M | $18.4M |
| Total current liabilities | $14.2M | $12.4M | $13.6M | $12.9M | $11.7M | $12.7M | $11.0M | $8.0M |
| Cash & equivalents | $2.7M | $4.0M | $7.8M | $12.5M | $9.5M | $6.5M | $2.9M | $5.4M |
| Marketable securities (current) | $3.8M | $3.8M | $4.8M | $141.0K | — | $2.0M | $0 | — |
| Property, plant & equipment | $138.0K | $152.0K | $166.0K | $184.0K | $202.0K | $221.0K | $239.0K | $317.0K |
| Other non-current assets | $128.0K | $126.0K | $224.0K | $219.0K | $216.0K | $215.0K | $213.0K | $123.0K |
| Accounts payable | $790.0K | $646.0K | $363.0K | $304.0K | $266.0K | $358.0K | $295.0K | $561.0K |
| Accrued liabilities | $1.4M | $1.3M | $938.0K | $990.0K | $926.0K | $909.0K | $840.0K | $2.3M |
| Other current liabilities | $1.1M | $937.0K | $822.0K | $676.0K | $612.0K | $1.4M | $780.0K | $1.1M |
| Other non-current liabilities | $4.4M | $4.2M | $4.0M | $3.8M | $3.8M | $3.7M | $3.7M | $3.7M |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$411.4M | -$410.6M | -$408.4M | -$406.3M | -$404.8M | -$402.9M | -$407.4M | -$396.3M |
| Accumulated other comprehensive income (loss) | $55.0K | $360.0K | $602.0K | $913.0K | $1.0M | $1.2M | $1.3M | $894.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.8M | -$3.3M | -$5.5M | -$4.2M | -$5.9M | -$4.2M | $982.0K | -$5.2M |
| Investing cash flow | -$5.0K | $4.5M | -$5.1M | -$1.2M | $10.8M | $6.3M | -$9.8M | -$2.2M |
| Financing cash flow | -$74.0K | -$4.2M | $2.0M | $3.0M | $0 | $0 | $1.8M | $21.9M |
| Free cash flow | -$3.8M | -$3.3M | -$5.5M | -$4.2M | -$5.9M | -$4.2M | $955.0K | -$5.4M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $50.0K | $27.0K | $197.0K |
| Share-based compensation | $575.0K | $461.0K | $167.0K | $166.0K | $145.0K | $244.0K | $399.0K | $827.0K |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts payable | $887.0K | $4.2M | $75.0K | $98.0K | -$272.0K | $23.0K | $38.0K | -$1.4M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating income | -$8.9M | -$8.8M | -$15.1M |
| Net income | -$1.0M | -$11.1M | -$21.0M |
| EPS (basic) | $-0.02 | $-0.28 | $-0.54 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Total assets | $25.9M | $34.3M | $24.8M |
| Total liabilities | $49.9M | $48.6M | $48.3M |
| Stockholders' equity | -$32.2M | -$32.9M | -$26.8M |
| Total current assets | $20.9M | $28.6M | $18.4M |
| Total current liabilities | $13.6M | $11.0M | $8.0M |
| Cash & equivalents | $7.8M | $2.9M | $5.4M |
| Marketable securities (current) | $4.8M | $0 | — |
| Property, plant & equipment | $166.0K | $239.0K | $317.0K |
| Other non-current assets | $224.0K | $213.0K | $123.0K |
| Accounts payable | $363.0K | $295.0K | $561.0K |
| Accrued liabilities | $938.0K | $840.0K | $2.3M |
| Other current liabilities | $822.0K | $780.0K | $1.1M |
| Other non-current liabilities | $4.0M | $3.7M | $3.7M |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$408.4M | -$407.4M | -$396.3M |
| Accumulated other comprehensive income (loss) | $602.0K | $1.3M | $894.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$19.8M | -$16.4M | -$16.5M |
| Investing cash flow | $10.8M | -$12.0M | -$100.0K |
| Financing cash flow | $5.0M | $26.8M | $4.0K |
| Free cash flow | -$19.8M | -$16.7M | -$16.6M |
| Capital expenditures | $50.0K | $224.0K | $100.0K |
| Share-based compensation | $722.0K | $2.3M | $770.0K |
| Deferred income taxes | $0 | $0 | $0 |
| Change in accounts payable | -$76.0K | -$607.0K | $326.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BYSI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-08-18 to 2026-03-20
Recent transactions
- Most recent: Huang Lan (Chief Executive Officer) — Gift of 260,582 shares on 2026-03-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Huang Lan | Chief Executive Officer | Gift | 2026-03-20 | 260,582 |
| Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2025-10-17 | 45,513 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-20 | Huang Lan | Chief Executive Officer | Gift | 260,582 | $0.00 |
| 2025-10-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 45,513 | $1.76 |
| 2025-10-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 85,798 | $1.72 |
| 2025-10-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 17,960 | $1.65 |
| 2025-10-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 28,495 | $1.65 |
| 2025-10-13 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 107,361 | $1.70 |
| 2025-10-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,390 | $1.77 |
| 2025-10-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,979 | $1.81 |
| 2025-10-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 7,507 | $1.77 |
| 2025-10-07 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,100 | $1.79 |
| 2025-10-06 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 17,500 | $1.78 |
| 2025-10-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 600 | $1.76 |
| 2025-10-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 600 | $1.73 |
| 2025-10-01 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,601 | $1.80 |
| 2025-09-30 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 4,464 | $1.81 |
| 2025-09-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 500 | $1.75 |
| 2025-09-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 600 | $1.68 |
| 2025-09-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 700 | $1.66 |
| 2025-09-24 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,256 | $1.68 |
| 2025-09-23 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 4,106 | $1.72 |
| 2025-09-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 5,410 | $1.83 |
| 2025-09-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,656 | $1.79 |
| 2025-09-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 5,307 | $1.74 |
| 2025-09-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,304 | $1.83 |
| 2025-09-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 840 | $1.88 |
| 2025-09-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,570 | $1.84 |
| 2025-09-12 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 700 | $1.85 |
| 2025-09-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,820 | $1.90 |
| 2025-09-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 8,176 | $1.93 |
| 2025-09-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 9,050 | $1.97 |
| 2025-09-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 7,090 | $1.93 |
| 2025-09-05 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 1,106 | $1.86 |
| 2025-09-04 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 803 | $1.82 |
| 2025-09-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 1,270 | $1.81 |
| 2025-09-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,800 | $1.78 |
| 2025-08-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 800 | $1.74 |
| 2025-08-28 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 809 | $1.81 |
| 2025-08-27 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 1,300 | $1.78 |
| 2025-08-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,000 | $1.79 |
| 2025-08-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 300 | $1.77 |
| 2025-08-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 2,376 | $1.75 |
| 2025-08-21 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,034 | $1.79 |
| 2025-08-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,456 | $1.74 |
| 2025-08-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 3,604 | $1.77 |
| 2025-08-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | Reporting person | Open market sale | 47,668 | $2.03 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-04 | View on SEC.gov → |
| 2026-05-15 | 4 | 2026-03-20 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-13 | 8-K | 2026-05-13 | View on SEC.gov → |
| 2026-04-08 | 4 | 2026-04-01 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-01 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-01 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-01 | View on SEC.gov → |
Recent news
Headlines about BYSI (BeyondSpring Inc. Ordinary Shares). Links open the publisher — we don’t host full articles.
-
BeyondSpring GAAP EPS of -$0.02
Seeking Alpha · 2026-08-17 -
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · 2026-08-14 -
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Yahoo Finance · 2026-06-04 -
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Yahoo Finance · 2026-06-02 -
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
Yahoo Finance · 2026-05-18 -
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)
Yahoo Finance · 2026-05-13 -
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Yahoo Finance · 2026-05-13 -
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · 2026-05-13
No headlines in this category right now — try “All”.